FDA Approved: DASATINIB — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA approved a supplemental application for dasatinib by Prasco Laboratories, enabling the marketing of a generic version. The drug is indicated for Philadelphi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
• Philadelphia Chromosome-positive Chronic Myeloid Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

SUPPL AP for DASATINIB (DASATINIB)